Development of Selective Covalent Janus Kinase 3 Inhibitors

Li Tan, Koshi Akahane, Randall McNally, Kathleen M.S.E. Reyskens, Scott B. Ficarro, Suhu Liu, Grit S. Herter-Sprie, Shohei Koyama, Michael J. Pattison, Katherine Labella, Liv Johannessen, Esra A. Akbay, Kwok Kin Wong, David A. Frank, Jarrod A. Marto, Thomas A. Look, J. Simon C. Arthur, Michael J. Eck, Nathanael S. Gray

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The Janus kinases (JAKs) and their downstream effectors, signal transducer and activator of transcription proteins (STATs), form a critical immune cell signaling circuit, which is of fundamental importance in innate immunity, inflammation, and hematopoiesis, and dysregulation is frequently observed in immune disease and cancer. The high degree of structural conservation of the JAK ATP binding pockets has posed a considerable challenge to medicinal chemists seeking to develop highly selective inhibitors as pharmacological probes and as clinical drugs. Here we report the discovery and optimization of 2,4-substituted pyrimidines as covalent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3. Investigation of structure-activity relationship (SAR) utilizing biochemical and transformed Ba/F3 cellular assays resulted in identification of potent and selective inhibitors such as compounds 9 and 45. A 2.9 Å cocrystal structure of JAK3 in complex with 9 confirms the covalent interaction. Compound 9 exhibited decent pharmacokinetic properties and is suitable for use in vivo. These inhibitors provide a set of useful tools to pharmacologically interrogate JAK3-dependent biology. (Chemical Equation Presented).

Original languageEnglish (US)
Pages (from-to)6589-6606
Number of pages18
JournalJournal of Medicinal Chemistry
Volume58
Issue number16
DOIs
StatePublished - Aug 27 2015

Fingerprint

Janus Kinase 3
Janus Kinases
STAT Transcription Factors
Pyrimidines
Immune System Diseases
Hematopoiesis
Structure-Activity Relationship
Innate Immunity
Cysteine
Pharmacokinetics
Adenosine Triphosphate
Pharmacology
Inflammation
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Tan, L., Akahane, K., McNally, R., Reyskens, K. M. S. E., Ficarro, S. B., Liu, S., ... Gray, N. S. (2015). Development of Selective Covalent Janus Kinase 3 Inhibitors. Journal of Medicinal Chemistry, 58(16), 6589-6606. https://doi.org/10.1021/acs.jmedchem.5b00710

Development of Selective Covalent Janus Kinase 3 Inhibitors. / Tan, Li; Akahane, Koshi; McNally, Randall; Reyskens, Kathleen M.S.E.; Ficarro, Scott B.; Liu, Suhu; Herter-Sprie, Grit S.; Koyama, Shohei; Pattison, Michael J.; Labella, Katherine; Johannessen, Liv; Akbay, Esra A.; Wong, Kwok Kin; Frank, David A.; Marto, Jarrod A.; Look, Thomas A.; Arthur, J. Simon C.; Eck, Michael J.; Gray, Nathanael S.

In: Journal of Medicinal Chemistry, Vol. 58, No. 16, 27.08.2015, p. 6589-6606.

Research output: Contribution to journalArticle

Tan, L, Akahane, K, McNally, R, Reyskens, KMSE, Ficarro, SB, Liu, S, Herter-Sprie, GS, Koyama, S, Pattison, MJ, Labella, K, Johannessen, L, Akbay, EA, Wong, KK, Frank, DA, Marto, JA, Look, TA, Arthur, JSC, Eck, MJ & Gray, NS 2015, 'Development of Selective Covalent Janus Kinase 3 Inhibitors', Journal of Medicinal Chemistry, vol. 58, no. 16, pp. 6589-6606. https://doi.org/10.1021/acs.jmedchem.5b00710
Tan L, Akahane K, McNally R, Reyskens KMSE, Ficarro SB, Liu S et al. Development of Selective Covalent Janus Kinase 3 Inhibitors. Journal of Medicinal Chemistry. 2015 Aug 27;58(16):6589-6606. https://doi.org/10.1021/acs.jmedchem.5b00710
Tan, Li ; Akahane, Koshi ; McNally, Randall ; Reyskens, Kathleen M.S.E. ; Ficarro, Scott B. ; Liu, Suhu ; Herter-Sprie, Grit S. ; Koyama, Shohei ; Pattison, Michael J. ; Labella, Katherine ; Johannessen, Liv ; Akbay, Esra A. ; Wong, Kwok Kin ; Frank, David A. ; Marto, Jarrod A. ; Look, Thomas A. ; Arthur, J. Simon C. ; Eck, Michael J. ; Gray, Nathanael S. / Development of Selective Covalent Janus Kinase 3 Inhibitors. In: Journal of Medicinal Chemistry. 2015 ; Vol. 58, No. 16. pp. 6589-6606.
@article{6721233b02104da39f4a18a02e4340df,
title = "Development of Selective Covalent Janus Kinase 3 Inhibitors",
abstract = "The Janus kinases (JAKs) and their downstream effectors, signal transducer and activator of transcription proteins (STATs), form a critical immune cell signaling circuit, which is of fundamental importance in innate immunity, inflammation, and hematopoiesis, and dysregulation is frequently observed in immune disease and cancer. The high degree of structural conservation of the JAK ATP binding pockets has posed a considerable challenge to medicinal chemists seeking to develop highly selective inhibitors as pharmacological probes and as clinical drugs. Here we report the discovery and optimization of 2,4-substituted pyrimidines as covalent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3. Investigation of structure-activity relationship (SAR) utilizing biochemical and transformed Ba/F3 cellular assays resulted in identification of potent and selective inhibitors such as compounds 9 and 45. A 2.9 {\AA} cocrystal structure of JAK3 in complex with 9 confirms the covalent interaction. Compound 9 exhibited decent pharmacokinetic properties and is suitable for use in vivo. These inhibitors provide a set of useful tools to pharmacologically interrogate JAK3-dependent biology. (Chemical Equation Presented).",
author = "Li Tan and Koshi Akahane and Randall McNally and Reyskens, {Kathleen M.S.E.} and Ficarro, {Scott B.} and Suhu Liu and Herter-Sprie, {Grit S.} and Shohei Koyama and Pattison, {Michael J.} and Katherine Labella and Liv Johannessen and Akbay, {Esra A.} and Wong, {Kwok Kin} and Frank, {David A.} and Marto, {Jarrod A.} and Look, {Thomas A.} and Arthur, {J. Simon C.} and Eck, {Michael J.} and Gray, {Nathanael S.}",
year = "2015",
month = "8",
day = "27",
doi = "10.1021/acs.jmedchem.5b00710",
language = "English (US)",
volume = "58",
pages = "6589--6606",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "16",

}

TY - JOUR

T1 - Development of Selective Covalent Janus Kinase 3 Inhibitors

AU - Tan, Li

AU - Akahane, Koshi

AU - McNally, Randall

AU - Reyskens, Kathleen M.S.E.

AU - Ficarro, Scott B.

AU - Liu, Suhu

AU - Herter-Sprie, Grit S.

AU - Koyama, Shohei

AU - Pattison, Michael J.

AU - Labella, Katherine

AU - Johannessen, Liv

AU - Akbay, Esra A.

AU - Wong, Kwok Kin

AU - Frank, David A.

AU - Marto, Jarrod A.

AU - Look, Thomas A.

AU - Arthur, J. Simon C.

AU - Eck, Michael J.

AU - Gray, Nathanael S.

PY - 2015/8/27

Y1 - 2015/8/27

N2 - The Janus kinases (JAKs) and their downstream effectors, signal transducer and activator of transcription proteins (STATs), form a critical immune cell signaling circuit, which is of fundamental importance in innate immunity, inflammation, and hematopoiesis, and dysregulation is frequently observed in immune disease and cancer. The high degree of structural conservation of the JAK ATP binding pockets has posed a considerable challenge to medicinal chemists seeking to develop highly selective inhibitors as pharmacological probes and as clinical drugs. Here we report the discovery and optimization of 2,4-substituted pyrimidines as covalent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3. Investigation of structure-activity relationship (SAR) utilizing biochemical and transformed Ba/F3 cellular assays resulted in identification of potent and selective inhibitors such as compounds 9 and 45. A 2.9 Å cocrystal structure of JAK3 in complex with 9 confirms the covalent interaction. Compound 9 exhibited decent pharmacokinetic properties and is suitable for use in vivo. These inhibitors provide a set of useful tools to pharmacologically interrogate JAK3-dependent biology. (Chemical Equation Presented).

AB - The Janus kinases (JAKs) and their downstream effectors, signal transducer and activator of transcription proteins (STATs), form a critical immune cell signaling circuit, which is of fundamental importance in innate immunity, inflammation, and hematopoiesis, and dysregulation is frequently observed in immune disease and cancer. The high degree of structural conservation of the JAK ATP binding pockets has posed a considerable challenge to medicinal chemists seeking to develop highly selective inhibitors as pharmacological probes and as clinical drugs. Here we report the discovery and optimization of 2,4-substituted pyrimidines as covalent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3. Investigation of structure-activity relationship (SAR) utilizing biochemical and transformed Ba/F3 cellular assays resulted in identification of potent and selective inhibitors such as compounds 9 and 45. A 2.9 Å cocrystal structure of JAK3 in complex with 9 confirms the covalent interaction. Compound 9 exhibited decent pharmacokinetic properties and is suitable for use in vivo. These inhibitors provide a set of useful tools to pharmacologically interrogate JAK3-dependent biology. (Chemical Equation Presented).

UR - http://www.scopus.com/inward/record.url?scp=84940515109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940515109&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.5b00710

DO - 10.1021/acs.jmedchem.5b00710

M3 - Article

VL - 58

SP - 6589

EP - 6606

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 16

ER -